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Low molecular weight heparins - their mode of action in plasma
and its consequences for the clinical laboratory
Suzette Bdguin and H. Coenraad Hemker
Department of Biochemistry, Cardiovascular Research Institute and University of Limburg, Maastricht, The
Netherlands
Introduction
Unfractionated heparin (UFH) has been with us as a drug since the 1930s and low
molecular weight heparins (LMWH) for some 20 years. This means that there is a fair
amount of established practice in dealing with these drugs. Research in the last few
years has made it clear that some of the traditional ways of approaching hcparins are
not necessarily the most adequate ones. lndeed there is a consrderable amou'rt of
confusion arising from attempts to define LMWHs in terms that are adequate to deal
with UFH. In this article we propose an approach to the clinical chemistry of heparins
based on recent biochemical data. We will indicate what the differences are with the
existing practice and we will show how existing practice can be brought in line with
the new approach.
Types of heparin
Heparin is a mixture of linear polysaccharides consisting of alternating iduronic acid
or glucoronate units and N-acetylglucoseamine units joined by glycosidic l-4
linkages. Most of the N-acetyls of the glucosamine are replaced by N-sulfo groups.
Most iduronates are O-sulfated in their 2-position, most glucosamines in their 6-
position. The result is that there is a wide variety of different possible mono-
saccharides. They occur in almost random order and the chain lengths can vary from
five to 100 or more. This chemical diversity is reflected in different biological
activities.
In order to be active in antithrombin III (ATIII) dependent reactions (see below),
heparin has to bind to ATIII via a specific pentasaccharide sequence. Heparins that
contain this sequence we call high affinity material (HAM). The low affinity material
(LAM) as such is not active in ATIII dependent reactions but may influence the
action of HAM by replacing it in nonspecific reactions (see below). The HAM comes
in two kinds: the material with a chain length of 5-17 monosaccharide units (MW
1700-5400) which is not capable of catalysing ATIII dependent thrombin activation.
We therefore call it below critical chain length material (BCLM). The HAM longer
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than l7 U, capable of catalysing thrombirr inactivation, we called above critical chain
length material (ACLM).
Biological activities of heparins
Apart from their anticoagulant action, heparins have a number of biological activities'
such as inducing the rellase of lipoprotein lipase and tissue factor pathway inhibitor
(TFPI) from the vessel wall. Here we will restrict ourselves to the effect of heparin
o n t h e b l o o d c o a g u l a t i o n p r o c e s s i n p l a s m a , b e c a u s e t h a t i s t h e b a s i s f o r t h e
assessment of the heparin effect in the clinical laboratory'
lt is essential to distinguish between specific and composite biological properties
of heparin, the former # ,f," specific biochemical reactions in which heparin 
is
active, the latter are consequencei of this activity in composite reaction systems'
The specific biologicai property of a heparin is its catalytic action in the
inactivarion of clotting [ro,"ur"rty ATIII. Theri are three main candidates' thrombin'
factor Xa and factor Ila. The inactivation of clotting factor XIa, XIIa and kallikrein
is also accelerated uy t"purin* but the effect is much smaller than that on the 
other
f a c t o r s ' A l s o c o n t a c t a c t i v a t i o n p r e s u m a b l y i s o n l y o f m i n o r i m p o r t a n c e i n
haemostasis and thrombosis. we, therefore, will not discuss these factors 
further'
Facror IXa inhibition, like thrombin requires ACLM, it contributes to the 
heparin
effect in the intrinsic system. Factor IXa inhibition is not at the basis of' 
nor does it
significantly contribute to, any current laboratory test so we,will not discuss 
it either'
In practice we are left with two specific biochemical actions of heparin' The 
first
i san t i fac to rXaact iv i t y , i .e . , theproper ty toca ta lyse the format ionofan inac t ive
complex between ATII! and factoi Xa. The second is antithrombin activity' 
i'e'' the
p r o p e r t y t o c a t a l y s e t h e f o r m a t i o n o f a n i n a c t i v e c o m p l e x b e t w e e n A T l l l a n d
thrombin . I t i s impor tan t tonote tha t the f i rs t i saproper tyo fa l lHAM,whereas the
)ropertyofACLMonly.Allheparins,indmanyothernegativelycharged
:atalysetheinact ivat ionofthrombinbyheparincofactor l l .Forthissuch
rationsofheparinarenecessaryasarerarelyattainedinclinicalpractice,
L
llow to express heParin activitY
Because the composite effects of heparin were known long before the specific effects'
the standardisation has until now been carried out in terms of clotting tests' 
It was
coagulation test to an arbitrary standard
rn is-known we can be more precise' HAM
fiJil::,ilTt1il * ff':HI"'Tl ;;
its antithrombin activitY.
1 t
In plasma without heparin, factor Xa is inactivated by its reaction with ATIII. The
reaction velocity is proportional to the concentration of ATIII and of factor Xa.
Because in clotting plasma ATIII is present in pM quantities (concentration in normal
plasma 2.24 t 0.M pM) and factor Xa in nM amounts (up to 20 nM), this means that
factor Xa disappears with a half-life time (tr) that is inversely proportional to the
ATIII concentration. In other words, the decay constant, ku"., is proportional to the
ATIII concentration. Heparin increases ku"", again proportionally to the HAM
concentration. This is the basis for the definition of our standard and method
independent unit of HAM activity. We define:
One unit of HAM activity is that amount of HAM that, in plasma with n pM
ATIII increases ko"" of factor Xa by n min-r.
Analogously we define:
One unit of ACLM activity is that amount of ACLM that, in plasma with n FM
ATIII increases ku"" of thrombin by n min-r.
It is important to note that the reaction conditions are defined to be as close as
possible to the conditions in which heparin acts in vivo: normal plasma, diluted as
few as the circumstances allow, and normal free Ca2* concentration (1.15-1.32 mM).
Any LMWH preparation now can be assigned a specific activity. The specific
activity is simply the amount of activity-units/unit weight (pG). Defining the specific
activity allows the determination of heparin concentrations in plasma. If, after
administration of HAM with a specific activity of S U/pG, we encounter a plasma
sample in which we measure an HAM activity of ZUlml than we can calculate the
amount of HAM material as being ZIS pGlml. Analogously we may calculate the
ACLM content and then obtain the BCLM content as HAM minus ACLM'
Composite heparin effects
In the body or in isolated plasma or blood the specific heparin actions cause a variety
of effects. [n vitro, e.g., they prolong the whole blood clotting time, the contact
activated clotting time, the activated partial thromboplastin time etc. [n vivo they
diminish a patients tendency to thrombosis and increase his tendency to bleed. All
these are composite actions of heparin because they are influenced by both the
antifacror Xa activity and the antithrombin activity. The relative contributions of both
activities to the various composite effects are not exactly known as yet. There is no
reason to assume that one composite action (e.g., the bleeding tendency), will depend
upon the specific effects (antithrombin activity, antithrombin Xa activity) in the same
manner as another (e.g., the antithrombotic effect). This is the rationale behind the
search for heparins with a more favourable distance between therapeutically active-
and potentially dangerous doses. Most tests use to screen for heparin activity in the
12
clinical laboratory (activated whole blood '
It ions.
ComParison of new and old units
in one test, will not necessarily mean an
endent waY'
The in vitro correlate to in vivo heparin action
antihaemostatic action' This is false' as ca
e.g., dermatan sulfate is a good antithron
t3
The search for a good laboratory correlate to the in vivo actions of 
heparin has
occupied us for severai;;.We have.good reasons to believe that 
the surface under
tt" tirro*uin generatio; curve (the endogenous thrombin potential, ETP) may serve
as such. Because thrombin is an enzyme, the amount of "work" 
that it can do is
proport ionaltoi tsconcentrat ionandtothet imethat i t isact ive.TheETPincreases
and decreases proportionally with the amount of thrombin generated 
in c|otting blood,
aswel laswi th the t imethat i t remainsac t ive . tndeedtheETP,un l i ke theAPTTand
other clotting times, i, d""r"or"d by all anticoagulant therapies 
(oral anticoagulation'
heparins,hirudin,dermatansulfate)andisincreasedincongenitalprothrombotic
"onditiont 
like ATIII deficiencY'
Werecent lydeve lopedaneasywaytodeterminetheETPinas ing lespec t ro -
photometric test. In th^is test an inefficient chromogenic substrate for 
thrombin is
added to the plasma, before coagulation is triggered. The thrombin 
that generates and
disappears will continuously coivert some oflhe substrate, but never 
more than about
| } v o o f t h e t o t a l a m o u n t a d d e d ' I n t h i s w a y t h e f i n a l a m o u n t o f c h r o m o g e n t c
substrate converted is proportional to the concintration-time integral 
of thrombin'
Heparin pharmacokinetics and pharmacodynamics
T h e e f f e c t o f h e p a r i n a d m i n i s t r a t i o n t o a p a t i e n t u n t i l n o w h a s u s u a l l y b e e nl ^ ^ l  ^ ^ ^ m r l a f i n n
determined bY clotting tests, l'e''i. ., the effect tf heparin on the blood 
coagulati
ffi:ffi'd ;'"r",,""..";"ru,t".',n""',te amounr of hefarin present. with the approach^- l  Tr/rT l i f  af far
,#"* ffi;iiJ pl*iur" ro derermine first the levels of ACLM and BGLM 
after
: . -  - L ^ - ^ - 6 - .  
" t t n h;:"'ff "^ffi:;##"";;;;;;;i;;:'iY'"T:::.:i:I:::::"*:il:""'i.'i":l
;::ilffi;,*"'l',l',"*f i"t""nution'th.rombuss,rowthT,9,-01"..",1'19^1131?;*ill]
;fi'tril:'r';"t;;;;tbb;" ,"purui" heparin pharmacokinetics from its 
pharmaco-
dynamics.
The relative importance of anti-Xa and antithrombin activity
ComparedtoUFH,LMWHsareenrichedinBCLM.Thismeansthattheirant i factor
Xa activity will be relatively more rm
Especially when expressed by comparlso
importani. By definition one unit of stand
Xa activity and one unit of antithrombin i
the antifactor Xa activity in plasma (norn
the presence and in the absence of ACLM
antiihrombin activity (normally 1'508 t
enhance the antifactor Xa activity in plasr
adding BCLM. That is what happens when LMWHs are administered' 
But is
enhancing the antifactor Xa activity in plasma an efficient means of 
inhibiting
thrombin production, admittedly the only possible effect of enhancing antifactor 
Xa
t4
activity? The answer is, that it iS not. The reason for this is easy to understand. 
The
prothrombin converting erzyme consists of a. stoichiometric complex of factor 
Xa and
factor Va adsorbed onio f.*oogulant phospholipids. The facto-r-present 
in the lowest
concentration limits ttre protfr.ofibinasl activity. This is factor Va' Actually 
factor Xa
i, fr"r"n, in clotting plurtnu in an about lo-fold 
excess. This means that one can
inhibit some 90Zo or?" factor Xa activity without altering the 
velocity of pro-
thrombin activation in clotting plasma. Factor Xa inhibition therefore 
is an inefficient
means of inhibiting tn.*fitiptoduction. This does not mean to say 
that it will not
work .PureBCLMs, l i ke theSynthe t icpentasacchar ide ,canbeg iven insuchh igh
amounts as to be efficient anticoagulants and hence efficient antithrombotics' 
It does
meanhoweverthattherelativeenrichmentofBCLMoverACLMinLMWHshasnot
muchinf luenceinvi tro.Nevertheless, invivotherearetwocircumstanceswhich
favour the effect of the BCLM injected with LMWHs. In the first place the biological
half-life time of BCLM; is signiiicantly longer rhan that of ACLMs, 
so that a "ftac-
tionation in vivo,, takes place, this mean-s that the relative amount 
of BCLM
circulating increases with time after injection. The second is that activated platelets
release platelet factor ;, that very efficiently neutratises AgLY but 
not BCLM'
Haemostasis and thrombosis inevitably entails platelet activation' hence 
pf 4 release'
In this way BCLM, but not ACLM, nluy 
"r"up" 
neutralisation at precisely those sites
where thrombosis occurs.
How to monitor heParin theraPY
If we need information on the heparin effect in a clinical situation we 
need one or
more of three things:-i; u quuntitaiive estimate of the overall effect in this 
patient at
this moment ;2) the level oi ACLM; and 3) the level of BCLM. Neither of these are
present lyava i lab le .Of ten theAPTTisusedtoassess theovera l le f fec t . I thas the
advanrage of being easy to determine and familiar. [t is relatively insensitive to
BCLMs and varies gr"uily with a large number of conditions in the patients 
plasma'
I talsoisnotveryprecise..ForassessingHAM(ACLM+BCLM)levelstheant i factor
Xa activity tests are in common use. They are useful tests but it should be 
taken into
account that the results are obtained in the absence of Ca2* ions' This means 
that the
absolutevaluesareoverest imatedwhenexpressed' l t" l . 'ofstandardUFHorany
standard that in its turn is compared to standard uFH' Proper standardisation 
of the
method could avoid these prollems. Often the thrombin time (TT) is used as an
antithrombin activity t"st. fi is relatively specific butimprecise' There is 
great need
for a good antithro;bin test for clinical use, capable of reliably measuring 
the ACLM
content.
The current opinions on the necessity and value of laboratory control arc obtained
with deficient tests and therefore 
"unnoi 
be claimed to be optimally founded' Yet one
may summarise the situation as follows:
1. In prophylactic heparin administration one can resort to standard dosage 
and
control of the rreparin effect is not necessary; at least it is not useful 
with the
2.
3 .
1 5
available tests because no correlation has been found with bleeding or (re)throm-
bosis.
There are indications that adjustment of therapeutic heparin doses to body weight
ameliorates the results of the therapy. tf adjusted doses are better than standard
doses, then it might be expected that adjustment on the effect of the administration
is better than adjustment on body weight. At present control of the APTT or of
antifactor Xa activity levels are used to control therapeutic heparin treatment. The
correlation with bleeding and/rethrombosis poor.
ln extracorporeal circulation there is a great need for specific heparin tests,
especially because often drugs are given (plasma expanders, aprotinin etc.) that
interfere with coagulation tests.
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